PCR analysis for common HIV-1 zidovudine resistance mutations in pol DNA of untreated and zidovudine treated patients.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

PCR analysis for common HIV-1 zidovudine resistance mutations in pol DNA of untreated and zidovudine treated patients.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:109 (poster no. 69). Unique Identifier : AIDSLINE ASHM5/94348929
Salem H; Nightingale B; Garsia RJ; Molecular Biology Department, Royal Prince Alfred Hospital,; Camperdown, NSW.

Abstract: METHODS: Mutations of the HIV-1 pol gene, causing amino acid changes at codons 41, 67, 70, 215 and 219, were sought in DNA of serial HIV-1 infected patients. Exposure to Zidovudine (ZDV) was nil in 12 cases and ranged from < 4 weeks to > 36 months in the remaining 55 samples. The PCR amplified two regions of pol encompassing the five codons of interest which were sequenced. RESULTS: The frequency of at least one mutated codon was 41% in ZDV naive patients and 100% after 3 years ZDV use. Codon 215 mutation, a high level ZDV resistance mutation, increased in prevalence after 24 months of ZDV and was seen in 57% of samples with > 36 months ZDV but in only 8% of those with 19-24 months ZDV. (see table below) CONCLUSION: Mutation in HIV-1 reverse transcriptase is common after ZDV exposure but also occurs in its absence. High level resistance mutation (codon 215) is uncommon until more than two years of ZDV monotherapy. TABULAR DATA, SEE ABSTRACT VOLUME.

Keywords: Amino Acid Sequence/GENETICS Codon Drug Resistance, Microbial/GENETICS Gene Expression Regulation, Viral/DRUG EFFECTS Genes, pol/*GENETICS Human HIV Infections/*DRUG THERAPY HIV-1/*DRUG EFFECTS/GENETICS Long-Term Care Mutation/*DRUG EFFECTS Polymerase Chain Reaction RNA-Directed DNA Polymerase/ANTAGONISTS & INHIB/GENETICS Zidovudine/*THERAPEUTIC USE ABSTRACT
941230
M94C4298

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .